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Bo Ahrén . Stefan Sjöberg . Jaako Tuomilehto . Marcus Lind
Received: June 18, 2019 / Published online: September 28, 2019
 The Author(s) 2019
ABSTRACT
Introduction: The effects of the GLP-1 ana-
logue liraglutide on time in hypoglycaemia,
time in hyperglycaemia, and time in range for
type 2 diabetes patients initially treated with
multiple daily insulin injections (MDI) were
investigated. Variables associated with hypo-
glycaemia in the current population were also
identified.
Methods: Analyses were based on data from a
previously performed double-blind, placebo-
controlled trial in which 124 MDI-treated
patients with type 2 diabetes were randomized
to liraglutide or placebo. Masked continuous
glucose monitoring (CGM) was performed at
baseline and week 24 in 99 participants.
Results: The mean time in hypoglycaemia was
similar for participants receiving liraglutide and
those receiving placebo after 24 weeks of treat-
ment. Mean time in target was greater in the
liraglutide group than in the placebo group: 430
versus 244 min/24 h (p\ 0.001) and 960 versus
695 min/24 h (p\ 0.001) for the two gly-
caemic ranges considered, 4–7 mmol/l and 4–
10 mmol/l, respectively. Mean time in hyper-
glycaemia was lower in the liraglutide group:
457 versus 723 min/24 h (p = 0.001) and 134
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versus 264 min/24 h (p = 0.023) for the two
cutoffs considered,[ 10 mmol/l
and[ 14 mmol/l, respectively. Lower mean
glucose level, lower C-peptide, and higher glu-
cose variability were associated with an
increased risk of hypoglycaemia in both treat-
ment groups. Higher proinsulin level was asso-
ciated with a lower risk of hypoglycaemia in the
liraglutide group.
Conclusion: For type 2 diabetes patients ini-
tially treated with MDI, introducing liraglutide
had a beneficial effect on glucose profiles esti-
mated by masked CGM. Mean glucose level,
glycaemic variability, C-peptide, and proinsulin
level influenced the risk of hypoglycaemia in
this population.
Trial Registration: ClinicalTrials.gov, number
(EudraCT nr: 2012-001941-42).
Funding: Novo Nordisk funded this study. The
Diabetes Research Unit, NU-Hospital Group
funded the journal’s Rapid Service Fee.
Keywords: Continuous glucose monitoring;
Hyperglycaemia; Hypoglycaemia; Liraglutide;
Placebo; Randomized clinical trial; Time in
range; Type 2 diabetes mellitus
INTRODUCTION
Optimal glycaemic control is required for
patients with type 2 diabetes (T2D) to minimize
the risk of secondary organ damage [1, 2].
Although several glucose-lowering treatments
are available, insulin therapy eventually
becomes necessary for many patients with T2D.
However, insulin treatment is associated with
side effects including hypoglycaemia and
weight gain [1, 3, 4]. Treatment options, for
example the combination of insulin with
insulin-sparing agents to minimize both insulin
dose and side effects, exist for patients with T2D
and high insulin requirements [5]. The most
advanced insulin regimen is generally multiple
daily insulin injections (MDI) in persons with
T2D, which is often used when other treatments
are insufficient [6].
Liraglutide is a glucagon-like peptide-1 (GLP-
1) receptor agonist that is administered subcu-
taneously once daily [7]. GLP-1 exerts several
physiological actions: it suppresses glucose-de-
pendent glucagon, delays gastric emptying, and
decreases appetite, and it has insulinotropic
effects [7, 8]. In earlier work, we found that,
compared with placebo, adding liraglutide
reduced HbA1c without increasing the risk of
hypoglycaemia as estimated by capillary glucose
levels in T2D patients treated with MDI [9].
However, HbA1c only provides information on
mean glucose level, not the extent to which low
and high glucose levels exist, nor glucose vari-
ability. Recently, there has been a greater focus
on continuous glucose monitoring (CGM),
which involves registering glucose levels every
fifth minute, as it is believed that CGM is
important if we are to fully understand the
effects of glucose-lowering treatments on glu-
cose levels [10]. Moreover, capillary glucose
checks are not an optimal way of determining
the risk of hypoglycaemia since they are highly
dependent on self-monitoring by the patient
when they feel symptoms of hypoglycaemia.
Some patients may ingest carbohydrates with-
out checking their glucose levels, they may not
have their meter available, or they may not feel
symptoms if their glucose levels are not very
low. Common CGM metrics used to evaluate
glucose-lowering treatments include time in
target, time in range, time in hyperglycaemia,
and time in hypoglycaemia.
Our aim in this study was to evaluate, using
masked CGM, the effect of liraglutide on glu-
cose levels as compared to placebo treatment in
T2D patients treated with MDI. We also
attempted to identify variables associated with
time in hypoglycaemia in these patients.
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METHODS
Patients and Study Procedures
The study design and the main outcomes of the
trial have previously been described in detail
[9, 11, 12]. The study was approved by the
ethics committee at the University of Gothen-
burg in accordance with the principles of the
Declaration of Helsinki. All participants gave
their written informed consent. Recruitment
occurred between February 2013 and February
2014. The study was registered in the EudraCT
database before it commenced (EudraCT No
2012-001941-42). The proposed design was a
randomized, double-blind trial lasting 24 weeks
that included patients with T2D and poor gly-
cemic control despite being treated with MDI
for at least six months.
Patients were randomized to liraglutide or
placebo, which were titrated from 0.6 mg dur-
ing the first week to 1.2 mg during the second
week to 1.8 mg from the third week onwards.
When initiating and increasing the dose of
liraglutide/placebo, the patients were advised to
temporarily reduce the insulin dose if the blood
glucose level was already on target in order to
avoid the potential risk of hypoglycaemia. After
the titration of liraglutide/placebo to 1.8 mg,
the insulin dose was increased again to the
original dose. Patients were advised to continue
to adjust their insulin dose throughout the
study as they had done previously.
The primary endpoint was the change in
HbA1c from baseline to week 24. Secondary
endpoints included the effects of treatment on
body weight and total insulin dose.
In brief, inclusion criteria were T2D patients
treated with MDI with or without metformin
(patients with premixed insulin were excluded),
HbA1c C 58 mmol/mol and B 102 mmol/mol,
BMI 27.5–45.0 kg/m2. Overall, 124 participants
were randomized 1:1 to subcutaneous liraglu-
tide or placebo [7, 9].
Patients had subcutaneous sensors (Dexcom
G4 PLATINUM system, San Diego, CA, USA)
that measured glucose values every fifth min-
ute. In the current study (MDI-Liraglutide 6),
masked CGM data were analyzed to compare
the effects of liraglutide and placebo on blood
glucose levels. Thus, masked CGM was per-
formed one week before randomization (run-in
period), in week 12, and before week 24. When
masked, the receiver did not display glucose
values and instead stored them for download-
ing. In total, 57 patients in the liraglutide group
and 50 patients in the placebo group had
masked CGM data at week 12. Masked CGM
data at week 24 were available for 52 patients in
the liraglutide group and 47 patients in the
placebo group. Liraglutide was added to insulin
therapy according to an algorithm described
previously [9, 11].
Glycaemic measures
We compared liraglutide treatment with pla-
cebo in terms of their effects on time in hypo-
glycaemia (\ 3.9 mmol/l and\ 3.0 mmol/l),
time in target (4–7 mmol/l), time in range (4–
10 mmol/l), and time in hyperglycaemia
([10 mmol/l and[ 14 mmol/l). Estimations
were performed for weeks 12 and 24; 24 weeks
was considered the main follow-up period. For
each glycaemic metric, estimations were per-
formed per 24 h, but they were also stratified
into daytime (06:00–22:00 and 06:00–24:00)
and nighttime (22:00–06:00 and 24:00–06:00)
estimations. We also estimated the mean
amplitude of glycaemic excursions (MAGE [13])
as a glucose variability measure.
Variables Associated with Hypoglycaemia
We estimated how time in hypoglycaemia at
weeks 12 and 24 was related to mean glucose
level as estimated by masked CGM during the
corresponding time period. In addition, we
evaluated possible baseline predictors for time in
hypoglycaemia (\3.0 mmol/l and\3.9 mmol/l,
respectively) at week 24. The following baseline
variables were evaluated as potential predictors:
age, sex, diabetes duration,HbA1c,mean glucose
level and standard deviation (SD) measured by
masked CGM, BMI, waist circumference,
abdominal sagittal diameter, waist-hip ratio,
fasting adiponectin level, fastingC-peptide level,
fasting proinsulin level, metformin use, total
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daily insulin dose, percent meal insulin of total
insulin dose, time in hypoglycaemia
(\3.0 mmol/l), and diabetes treatment satisfac-
tion status scale (DTSQ). For the predictors that
were statistically significant in the liraglutide
group at the 5% level, we also evaluated whether
their predictive abilities were significantly
stronger in the liraglutide group compared with
the placebo group through interaction analysis.
Laboratory Analyses
All laboratory analyses were performed at the
Karolinska University Hospital, Stockholm,
Sweden. HbA1c was measured according to the
International Federation of Clinical Chemistry
(IFCC) method, with all values converted
according to the National Glycosylation Stan-
dard Program (NGSP) for dual reporting [14]. A
commercially available ELISA kit from Mercodia
AB was used to measure proinsulin.
Statistics
For descriptive purposes, data are presented
here as mean (SD), median (minimum, maxi-
mum) for continuous variables and as number
(%) for categorical variables. For comparisons
between groups, Fisher’s nonparametric per-
mutation test was used for continuous variables,
Fisher’s exact test for dichotomous variables,
the Mantel–Haenszel chi-square test for ordered
categorical variables, and the Pearson chi-square
test for non-ordered categorical variables. For all
tests, p\ 0.05 was considered statistically
significant.
Analysis of the percent of time in hypogly-
caemia in relation to the CGM mean and vari-
ous baseline predictors was performed using a
log-linear quasi-binomial model with robust
standard errors, accounting for the positive,
skewed, and heteroscedastic distribution of
percent of time in hypoglycemia. In prediction
analyses, the baseline variables were analyzed
one at a time and further adjusted for time in
hypoglycaemia at baseline and CGM mean. An
interaction between the predictor and treat-
ment group was included to test whether the
effect of the predictor differed between
treatment groups, in order to eliminate spurious
correlations due to study-related causes and
phenomena such as regression to the mean.
RESULTS
Baseline Characteristics
Baseline characteristics for the original cohort
(FAS population), including all patients with at
least one HbA1c measurement during follow-up
(n = 122), are shown in Table 1 along with
patients with CGM data at week 24 (n = 99).
There were no clear differences between the FAS
population and the currently evaluated popu-
lation with CGM information in terms of age,
sex, HbA1c, CGM glucose profiles, or other
patient characteristics (Table 1).
For the cohort with CGM data, there were no
significant differences between patients receiv-
ing liraglutide and those receiving placebo
(Table 1); 19 (36.5%) and 16 (34.0%) were
women, respectively. The mean age in both
groups was 64 (8.2) years. Mean HbA1c was 73.6
(11.0) vs. 74.5 (12.1) mmol/mol (8.9% (1.0) vs.
9.0% (1.1%), BMI was 33.8 (4.2) vs. 33.3 (3.9)
kg/m2, total insulin dose was 105.7U (47.2) vs.
107.2U (42.1), and number of insulin injections
daily was 4.5 (0.9) vs. 4.4 (0.6) in the two
groups, respectively.
Overall Effects of Liraglutide and Placebo
on Time in Hypoglycaemia, Time
in Range, and Time in Hyperglycaemia
At week 24 (end of the follow-up period), there
was no difference in time in hypoglycaemia
between patients receiving liraglutide and those
receiving placebo (Table 2); mean time in
hypoglycaemia\3.9 mmol/l was 19.5 (34.2) vs.
19.3 (32.3) min/24 h, respectively, p = 0.97, and
mean time in hypoglycaemia\ 3.0 mmol/l was
3.5 (7.5) vs. 4.3 (11.2) min/24 h, p = 0.67.
Time in range (4–10 mmol/l) at week 24 was
significantly greater for liraglutide-treated
patients: 960 (346) vs. 695 (393) min/24 h for
liraglutide- and placebo-treated patients,
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Table 1 Demographics and baseline characteristics of 122 subjects in the ITT population and 99 subjects with masked
CGM data obtained at 24 weeks of follow-up
Variable ITT population (n = 122) Masked CGM data obtained at week



























Female 23 (36.5%) 20 (33.9%) 0.91 19 (36.5%) 16 (34.0%) 0.96
White race 62 (98.4%) 59 (100.0%) 0.33 52 (100.0%) 47 (100.0%) 1.00
Hispanic or Latino 2 (3.2%) 0 (0.0%) 0.17 1 (1.9%) 0 (0.0%) 0.34
Smoking status
Never a smoker 26 (41.3%) 21 (35.6%) 20 (38.5%) 17 (36.2%)
Former smoker 29 (46.0%) 31 (52.5%) 26 (50.0%) 25 (53.2%)
Current smoker 8 (12.7%) 7 (11.9%) 0.69 6 (11.5%) 5 (10.6%) 0.92
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Table 1 continued
Variable ITT population (n = 122) Masked CGM data obtained at week
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Table 1 continued
Variable ITT population (n = 122) Masked CGM data obtained at week
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Table 1 continued
Variable ITT population (n = 122) Masked CGM data obtained at week



























Metformin users 43 (68.3%) 43 (72.9%) 0.72 33 (63.5%) 34 (72.3%) 0.47







































































MI 6 (9.5%) 10 (16.9%) 0.34 5 (9.6%) 9 (19.1%) 0.28
Stroke 1 (1.6%) 0 (0.0%) 1.00 0 (0.0%) 0 (0.0%) 1.00
PCI 5 (7.9%) 8 (13.6%) 0.48 4 (7.7%) 7 (14.9%) 0.41
Bypass surgery 5 (7.9%) 7 (11.9%) 0.67 5 (9.6%) 4 (8.5%) 1.00
Retinopathy 9 (14.3%) 14 (23.7%) 0.27 7 (13.5%) 12 (25.5%) 0.20
Amputation 0 (0.0%) 1 (1.7%) 0.97 0 (0.0%) 1 (2.1%) 0.95
Past foot ulcer 3 (4.8%) 4 (6.8%) 0.93 2 (3.8%) 3 (6.4%) 0.90
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respectively, p\0.001 (Table 2). Regarding
high glucose values ([10 mmol/l), placebo-
treated patients spent 58% more time in this
range: 723 (409) min/24 h vs. 457 (362),
p = 0.001. Placebo-treated patients spent 97%
more time with glucose levels higher than
14 mmol/l.
Time in hypoglycaemia, time in range, and
time in hyperglycaemia at week 12 are pre-
sented in Table 2. Similar patterns for the dif-
ferent glycaemic metrics were seen at weeks 12
and 24 for liraglutide-treated compared to pla-
cebo-treated patients except that liraglutide-
treated patients spent more time in hypogly-
caemia\ 3.0 mmol/l at week 12 (6.3 [14.5] vs.
1.5 [4.5] min/24 h, p = 0.023).
Times Spent in Diurnal and Nocturnal
Hypoglycaemia
Time in hypoglycaemia, time in target, time in
range, and time in hyperglycaemia stratified
into diurnal and nocturnal hours for patients
receiving liraglutide and placebo at weeks 12
and 24 are shown in Table S1 of the Electronic
supplementary material (ESM). There were
similar patterns for diurnal and nocturnal
hypoglycaemia to those seen for overall esti-
mations per 24 h (Table 2 and Table S1 in the
ESM). Time in range (4–10 mmol/l) was signifi-
cantly greater for patients receiving liraglutide
during both the daytime and the nighttime
(Fig. 1), and time in hyperglycaemia ([10
and[ 14 mmol/l) was significantly greater for
placebo-treated patients. Regarding time in
hypoglycaemia, there was a similar pattern to
that seen in the overall analyses, with no differ-
ences in time spent in either diurnal or nocturnal
hypoglycaemia\3.9 mmol/l or\3.0 mmol/l
between the liraglutide-treated and placebo-
treated patients at week 24. At week 12, time in
nocturnal hypoglycaemia\3.0 mmol/l was sig-
nificantly greater in patients receiving liraglutide
than in those receiving placebo, whereas there
was no difference in time in diurnal hypogly-
caemia (Table S1 in the ESM).
Relationship of Mean Glucose Level
with Hypoglycaemia
There was a significant association of increased
risk of time in hypoglycaemia with lower mean
glucose levelmeasured bymasked CGM. This was
evident inboth the liraglutide andplacebogroups
for both the \3.0 mmol/l and\3.9 mmol/l
glucose levels (Fig. 2).
At week 24, there was a pattern of less hypo-
glycaemia (3.9 mmol/l) in the liraglutide group
than in the placebo group at the same mean
glucose level. At week 24, those on liraglutide
who had relatively high mean glucose levels
spent less time hypoglycaemia \3.0 mmol/l
(Fig. 2). At week 12, there was no difference in
time in hypoglycaemia \3.9 mmol/l between
the treatment groups at a similar glucose level,
whereas there was a tendency for more time in
hypoglycaemia\3.0 mmol/l in the liraglutide
group (Fig. 2).
Table 1 continued
Variable ITT population (n = 122) Masked CGM data obtained at week










Current foot ulcer 0 (0.0%) 0 (0.0%) 1.00 0 (0.0%) 0 (0.0%) 1.00
n (%) is presented for categorical variables
Mean (SD)/median (min; max)/n is presented for continuous variables
For comparisons between groups, Fisher’s exact test was used for dichotomous variables, the Mantel–Haenszel chi-square
test was used for ordered categorical variables, Pearson’s chi-square test was used for non-ordered categorical variables, and
Fisher’s nonparametric permutation test was used for continuous variables
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Baseline Variables Predicting Time
in Hypoglycemia
Analyses of baseline variables in relation to time
in hypoglycaemia (\3.0 mmol/l or\3.9 mmol/l)
at weeks 12 and 24 during liraglutide and pla-
cebo treatment and their interactions are shown
in Table S2 of the ESM. Higher variability of
glucose levels at baseline as measured by CGM-
SD predicted more time in hypogly-
caemia\ 3.9 mmol/l in both the liraglutide
group at week 24 (p = 0.021) and the placebo
group (p = 0.003), but there was no interaction
with treatment (p = 0.42). Higher C-peptide
predicted less time in hypoglycaemia in the
liraglutide (p = 0.006) and placebo (p = 0.019)
groups but did not differ between treatments
(p = 0.78). Higher proinsulin was associated
with less time in hypoglycaemia in the liraglu-
tide group (p\0.001), but not in the placebo
group (p = 0.19), and there was a significant
treatment interaction (p = 0.021). Greater
treatment satisfaction at baseline estimated by
DTSQ was associated with more time in hypo-
glycaemia for the liraglutide group (p = 0.026),
but there was no such association for the pla-
cebo group, and there was no interaction with
treatment.
Higher baseline proinsulin was also associated






































































































































































































































































































































































Fig. 1 Times in range (4–10 mmol/l) during the daytime
and nighttime at the 24-week follow-up among liraglutide-
treated and placebo-treated patients. Time in range was
significantly greater during liraglutide treatment. Error bars
represent 95% confidence intervals
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week 24 in the liraglutide group (p = 0.010), and
there was a significant treatment interaction
(p = 0.045). Higher mean baseline glucose mea-
sured via CGM was associated with less time in
hypoglycaemia in the liraglutide group
(p = 0.040), and there was a significant treatment
interaction (p = 0.004). For the liraglutide group,
baseline treatment satisfaction was associated
with more time in hypoglycaemia (p = 0.011),
and there was no treatment interaction
(p = 0.77).
DISCUSSION
This randomized trial of liraglutide or placebo
treatment in T2D patients already treated with
MDI showed that glucose profiles estimated by
masked CGM are significantly improved by
liraglutide treatment. During liraglutide treat-
ment, more time was spent at target glucose
levels and less time at very high glucose levels.
Time in hypoglycaemia was strongly associated
with mean glucose level in both liraglutide- and
placebo-treated patients. In addition, patients
with lower fasting C-peptide levels and higher
glycaemic variability had a greater risk of
hypoglycaemia during MDI treatment with or
without simultaneous liraglutide treatment.
Those with higher proinsulin levels benefitted
more from liraglutide treatment in terms of the
reduction in time in hypoglycaemia.
Strengths of the current study include the
randomized placebo-controlled design and
repeated evaluations by masked CGM. Also, we
evaluated variables associated with hypogly-
caemia in both groups, as well as whether there
was a treatment interaction. Limitations
include the moderate size of the study, such
that smaller effects may not have been detected.
Another limitation is that not all patients had
masked CGM data during follow-up (99 of 124
randomized patients). However, patient char-
acteristics at baseline were similar for the
bFig. 2 Percent time in hypoglycaemia (\ 3.0 or \ 3.9
mmol/l) vs CGM for the liraglutide-treated and placebo-
treated patients at the 12- and 24-week follow-ups. The
risk of hypoglycaemia increased rapidly with decreasing
glucose level in both treatment groups
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liraglutide-treated and the placebo-treated
patients with CGM data during follow-up.
It is of interest to understand whether
liraglutide stabilizes glucose levels in T2D
patients treated with MDI (i.e. whether it redu-
ces the risk of hypoglycaemia). Some of our
results support this hypothesis. At week 24 (the
end of the study), patients treated with liraglu-
tide had significantly more time in range with-
out incurring more time in hypoglycaemia
(below either 3.9 or 3.0 mmol/l). We also
attempted to investigate this issue by compar-
ing the risk of hypoglycaemia at similar mean
glucose levels in both treatment groups. This
approach was limited, however, by the fact that
few of the patients in the placebo group had low
mean glucose levels, meaning that randomized
comparisons were not possible. To definitively
determine whether liraglutide reduces the risk
of hypoglycaemia in MDI-treated T2D patients,
a randomized trial obtaining similar mean glu-
cose levels in both treatment arms is needed.
It has been thought that a major barrier to
obtaining good glycaemic control during insu-
lin treatment is that the risk of hypoglycaemia
increases when the mean glucose level is
reduced [15]. This view has, however, been
challenged in certain studies both among T1D
and T2D [16, 17]. Other factors, such as poor
experiences with hypoglycaemia, adequate
insulin dose adjustments, concomitant glucose-
lowering treatments, and unstable glucose
metabolism may also be important when
attempting to lower HbA1c and the corre-
sponding risks of hypoglycaemia. However, the
current study confirms that mean glucose level
is strongly associated with risk of hypogly-
caemia during MDI treatment in T2D patients
with and without simultaneous incretin-based
therapy. More time in hypoglycaemia has been
associated with an increased risk of severe
hypoglycaemia [18]. Hypoglycaemia has also
been associated with an increased risk of car-
diovascular disease and a lower quality of life
[4, 19–21].
Longer duration of insulin treatment has
been associated with risk of hypoglycaemia in
T2D patients [22, 23]. Longer diabetes duration
has been associated with impaired glycaemic
control and more extensive glucose-lowering
treatments where MDI is generally a second- or
third-line insulin regimen [6, 24]. In the current
study, mean diabetes duration was 17 years. On
average, patients performed [ 4 insulin injec-
tions per day. Although all of the patients
endogenously produced insulin (C-pep-
tide[0.1 nmol/l was an inclusion criterion),
the level was essential for hypoglycaemia risk.
The pancreas has likely a better possibility of
adjusting insulin doses when exogenous insulin
was not optimally administered. The lower risk
of hypoglycaemia in liraglutide-treated patients
with high proinsulin levels indicates that
proinsulin level is associated with the strength
of glucose-stabilizing effects. High proinsulin
levels have also been associated with a greater
HbA1c reduction by liraglutide [25]. Fasting
proinsulin has been shown to be a marker of
insulin resistance [26]. Whether proinsulin can
be used as a marker for the glucose-stabilizing
effects of liraglutide needs to be evaluated in
further studies.
T2D patients treated with MDI likely benefit
from a reduction in long-term complications
due to improved 24-h glucose profiles.
Improvements in both daytime and nighttime
glucose profiles occurred in the current study.
Time in range (4–10 mmol/l) was 38% higher
with liraglutide treatment. Placebo-treated
patients had 58% more time with glu-
cose[10 mmol/l. Time with very high glucose
levels ([14 mmol/l), which are of specific
concern in relation to diabetes complications,
was 97% greater with placebo treatment, corre-
sponding to[ 2 h more per 24-h period. These
estimates highlight the efficacy of liraglutide,
which would not be so apparent if we only
evaluated HbA1c. The glucose-lowering effects
of liraglutide were obtained even though the
patients receiving liraglutide treatment took
considerably less insulin per 24 h [9].
The LEADER trial, which showed beneficial
effects on cardiovascular disease of liraglutide
treatment in T2D patients, did not include
patients treated with MDI [27]. The current
study shows that liraglutide treatment lowers
glucose levels and reduces time in hypogly-
caemia in T2D patients treated with MDI, and is
therefore likely to reduce diabetes
complications.
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Moreover, results from the current study
imply that in clinical practice, healthcare pro-
fessionals should pay attention to T2D patients
receiving MDI treatment who have low mean
glucose levels, low insulin production, and high
glucose variability in relation to hypoglycaemia
risk. Patients with higher proinsulin levels had a
reduced risk of hypoglycaemia when they were
treated with liraglutide, given the resulting
mean glucose levels. Time may be essential for
insulin titration in conjunction with treatment
with GLP-1 analogues. In the current study,
there were some indications that time in
hypoglycaemia with liraglutide was greater at
week 12 than at week 24.
CONCLUSION
In conclusion, the current study using masked
CGM data supports the notion that liraglutide is
a valid treatment option for T2D patients trea-
ted with MDI. Introducing liraglutide in this
patient population increased time in range and
substantially reduced time with very high glu-
cose levels without incurring any marked
increase in the risk of hypoglycaemia. MDI-
treated T2D patients with low C-peptide levels
and greater glycaemic variability were found to
have a greater risk of hypoglycaemia. Proinsulin
was related to the glucose-stabilizing effect of
liraglutide.
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